| scholarly article | Q13442814 |
| P50 | author | Roderick Bronson | Q7356595 |
| Matthew Meyerson | Q47451221 | ||
| Ignacio I Wistuba | Q74766086 | ||
| Heidi Greulich | Q32646847 | ||
| Kwok Kin Wong | Q42687956 | ||
| P2093 | author name string | Masaya Takahashi | |
| Liang Chen | |||
| Sara Zaghlul | |||
| Lucian R Chirieac | |||
| Flavio Solca | |||
| Geoffrey I Shapiro | |||
| Danan Li | |||
| Hongbin Ji | |||
| Takeshi Shimamura | |||
| Robert F Padera | |||
| Maria G Raso | |||
| Christa L Borgman | |||
| Kathleyn A Brandstetter | |||
| Shigeto Kubo | |||
| Pilar Garin Chesa | |||
| Samanthi A Perera | |||
| Ulrich Guertler | |||
| P2860 | cites work | Synergistic interaction of p185c-neu and the EGF receptor leads to transformation of rodent fibroblasts | Q42797529 |
| Adenosquamous carcinoma of the lung: radiologic appearance | Q72074348 | ||
| HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors | Q24297102 | ||
| BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models | Q24649935 | ||
| The crystal structure of a truncated ErbB2 ectodomain reveals an active conformation, poised to interact with other ErbB receptors | Q27640631 | ||
| Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer. | Q27824805 | ||
| The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies | Q27851393 | ||
| Untangling the ErbB signalling network | Q27860884 | ||
| Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes | Q28343950 | ||
| The site of HIV-1 integration in the human genome determines basal transcriptional activity and response to Tat transactivation | Q28361880 | ||
| ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling | Q33886341 | ||
| Lung cancer: intragenic ERBB2 kinase mutations in tumours | Q34354426 | ||
| Trastuzumab in the treatment of non-small cell lung cancer. | Q34563711 | ||
| The role of HER2/neu expression and trastuzumab in non-small cell lung cancer | Q35674579 | ||
| Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? | Q35908976 | ||
| Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis | Q36072192 | ||
| The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors | Q36542428 | ||
| Molecular mechanisms of epidermal growth factor receptor (EGFR) activation and response to gefitinib and other EGFR-targeting drugs | Q36692592 | ||
| Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy | Q40110906 | ||
| The major lung cancer-derived mutants of ERBB2 are oncogenic and are associated with sensitivity to the irreversible EGFR/ERBB2 inhibitor HKI-272. | Q40169126 | ||
| Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. | Q40449400 | ||
| Oncogenic potential of erbB-2 in human mammary epithelial cells | Q41677558 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| P304 | page(s) | 474-479 | |
| P577 | publication date | 2009-01-02 | |
| P1433 | published in | Proceedings of the National Academy of Sciences of the United States of America | Q1146531 |
| P1476 | title | HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy | |
| P478 | volume | 106 |
| Q33605906 | A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer |
| Q35782291 | A systematic analysis of the resistance and sensitivity of HER2YVMA receptor tyrosine kinase mutant to tyrosine kinase inhibitors in HER2-positive lung cancer |
| Q36910173 | Acquired substrate preference for GAB1 protein bestows transforming activity to ERBB2 kinase lung cancer mutants |
| Q54986604 | Activating HER2 mutations as emerging targets in multiple solid cancers. |
| Q36785721 | Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment |
| Q93159538 | Advances in HER2-Targeted Therapy: Novel Agents and Opportunities Beyond Breast and Gastric Cancer |
| Q39731829 | Afatinib (BIBW 2992) development in non-small-cell lung cancer |
| Q38270627 | Afatinib and lung cancer. |
| Q38646686 | Afatinib-based combination regimens for the treatment of solid tumors: rationale, emerging strategies and recent progress |
| Q88377651 | An EGFR ligand promotes EGFR-mutant but not KRAS-mutant lung cancer in vivo |
| Q28472663 | Analysis of compound synergy in high-throughput cellular screens by population-based lifetime modeling |
| Q26797471 | Analysis of different HER-2 mutations in breast cancer progression and drug resistance |
| Q35623056 | Anti-tumour activity of afatinib, an irreversible ErbB family blocker, in human pancreatic tumour cells |
| Q36495936 | Antitumor effect of afatinib, as a human epidermal growth factor receptor 2-targeted therapy, in lung cancers harboring HER2 oncogene alterations |
| Q27612411 | CIViC database |
| Q48316419 | Clinical and pathological characterization of HER2 mutations in human breast cancer: a systematic review of the literature. |
| Q58698588 | Clinical characterization of ERBB2 exon 20 insertions and heterogeneity of outcomes responding to afatinib in Chinese lung cancer patients |
| Q49136595 | Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer |
| Q39034581 | Comparable clinical outcomes in patients with HER2-mutant and EGFR-mutant lung adenocarcinomas |
| Q33963199 | EGFR exon 20 insertion mutations in non-small-cell lung cancer: preclinical data and clinical implications |
| Q37767383 | EGFR inhibitors in non-small cell lung cancer (NSCLC): the emerging role of the dual irreversible EGFR/HER2 inhibitor BIBW 2992. |
| Q93081689 | ERBB2 Regulates MED24 during Cancer Progression in Mice with Pten and Smad4 Deletion in the Pulmonary Epithelium |
| Q91775935 | Emergence of ERBB2 Mutation as a Biomarker and an Actionable Target in Solid Cancers |
| Q36177675 | Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China |
| Q36346641 | Extreme Outlier Analysis Identifies Occult Mitogen-Activated Protein Kinase Pathway Mutations in Patients With Low-Grade Serous Ovarian Cancer |
| Q93009474 | Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers |
| Q36336795 | Ganetespib (STA-9090), a nongeldanamycin HSP90 inhibitor, has potent antitumor activity in in vitro and in vivo models of non-small cell lung cancer. |
| Q49678076 | Genomic alterations of ERBB receptors in cancer: clinical implications |
| Q39622232 | Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). |
| Q98771158 | HER2 Exon 20 Insertion Mutations in Lung Adenocarcinoma: Case Series and Response to Pyrotinib |
| Q38153447 | HER2 and lung cancer |
| Q26866534 | HER2 driven non-small cell lung cancer (NSCLC): potential therapeutic approaches |
| Q38661973 | HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium. |
| Q37065678 | How genetically engineered mouse tumor models provide insights into human cancers |
| Q35024472 | Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis. |
| Q35196603 | Identification of five driver gene mutations in patients with treatment-naïve lung adenocarcinoma in Taiwan |
| Q37376100 | Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer |
| Q39741320 | Lung cancers unrelated to smoking: characterized by single oncogene addiction? |
| Q52568478 | Mechanisms and clinical activity of an EGFR and HER2 exon 20-selective kinase inhibitor in non-small cell lung cancer. |
| Q36942619 | Mechanisms of resistance to reversible inhibitors of EGFR tyrosine kinase in non-small cell lung cancer. |
| Q24606677 | Molecular biology of lung cancer |
| Q24610335 | Molecular biology of lung cancer: clinical implications |
| Q35136424 | Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 |
| Q90257652 | Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma |
| Q60445017 | Mutation de l’EGFR, de l’étude du gène à la pratique clinique : exemplarité ou exception ? |
| Q36547123 | Natural history and molecular characteristics of lung cancers harboring EGFR exon 20 insertions. |
| Q34161395 | New driver mutations in non-small-cell lung cancer |
| Q36660677 | New targetable oncogenes in non-small-cell lung cancer |
| Q38073157 | Other signalization targets |
| Q40605757 | Outcomes of chemotherapies and HER2 directed therapies in advanced HER2-mutant lung cancers. |
| Q36694995 | Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors |
| Q90528249 | Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity |
| Q37776547 | Personalized therapies in the cancer "omics" era |
| Q39297048 | Preclinical and clinical development of afatinib: a focus on breast cancer and squamous cell carcinoma of the head and neck |
| Q35671830 | Prevalence and Clinicopathological Characteristics of HER2 and BRAF Mutation in Chinese Patients with Lung Adenocarcinoma |
| Q37398636 | Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas. |
| Q36927538 | Pulse Afatinib for ERBB2 Exon 20 Insertion-Mutated Lung Adenocarcinomas. |
| Q37992086 | Quinazoline derivatives as potential anticancer agents: a patent review (2007 - 2010). |
| Q39802930 | Resequencing and copy number analysis of the human tyrosine kinase gene family in poorly differentiated gastric cancer |
| Q43387391 | Response Heterogeneity of EGFR and HER2 Exon 20 Insertions to Covalent EGFR and HER2 Inhibitors |
| Q26781683 | Role of HER2 in NSCLC |
| Q93185180 | Second-generation EGFR and ErbB tyrosine kinase inhibitors as first-line treatments for non-small cell lung cancer |
| Q37229404 | Sensitive methods for the detection of an insertion in exon 20 of the HER2 gene in the metastasis of non-small cell lung cancer to the central nervous system |
| Q30574736 | Survival and death signals can predict tumor response to therapy after oncogene inactivation |
| Q35737325 | Targetable "driver" mutations in non small cell lung cancer. |
| Q35200528 | Targeted therapy in NSCLC driven by HER2 insertions |
| Q47213006 | Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib. |
| Q27853154 | Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors |
| Q104289124 | Targeting Infrequent Driver Alterations in Non-Small Cell Lung Cancer |
| Q38352587 | The Potential of panHER Inhibition in Cancer |
| Q41891513 | The genomics of lung adenocarcinoma: opportunities for targeted therapies |
| Q33823191 | The use of molecular imaging combined with genomic techniques to understand the heterogeneity in cancer metastasis |
| Q53702598 | Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations. |
| Q92895800 | Treatment outcome and clinical characteristics of HER2 mutated advanced non-small cell lung cancer patients in China |
| Q36544650 | Tumor driven by gain-of-function HER2 H878Y mutant is highly sensitive to HER2 inhibitor |
| Q55020045 | [Mechanism of action and preclinical development of afatinib]. |
Search more.